Regaining compliance with Nasdaq listing requirements is a positive development for Adial Pharmaceuticals, as it removes the immediate risk of delisting, which can be a concern for investors and can affect the stock's liquidity and attractiveness. This news is likely to be viewed positively by the market in the short term, leading to an increase in the stock price.